According to estimations provided by GLOBOCON for Sri Lanka, the year 2018 witnessed a staggering toll of 23,530 newly diagnosed cases of cancer, accompanied by a distressing count of 14,013 cancer-related deaths. Such figures paint a stark picture of the gravity of the situation, with the burden of cancer-related morbidity and mortality looming ominously over the nation’s healthcare landscape. Moreover, projections indicate a sharp increase in trajectory, with an anticipated annual increase of 23% in cancer cases until the year 2030, further exacerbating the strain on healthcare resources and infrastructure.

In light of these sobering statistics, the imperative to provide equitable access to cutting-edge medicines and pioneering research endeavors for oncology patients cannot be overstated. RemediumOne, recognizing this urgent need, has taken proactive steps to collaborate closely with oncologists in Sri Lanka, striving to bridge the gap between patients and innovative treatment options.

A recent dialogue conducted with key opinion leaders (KOLs) in the field of oncology underscored the importance of enhancing the capacity for oncology trials within Sri Lanka.